1.	Does a Single Steroid Injection Reduce the Formation of Postmastectomy Seroma Phase: Phase IV Type: Supportive care, Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: seromprotocol, NCT00307606
2.	Unrelated Double Umbilical Cord Blood Units Transplantation Phase: Phase III, Phase II Type: Treatment Status: Active Age: 1 to 50 Sponsor: Other Protocol IDs: HORCSCT-0902, NCT01015742
3.	Clofarabine or High-Dose Cytarabine, Pegaspargase, and Combination Chemotherapy Followed by Daunorubicin Hydrochloride or Doxorubicin Hydrochloride in Treating Young Patients With Acute Lymphoblastic Leukemia Phase: Phase III, Phase II Type: Treatment Status: Active Age: 1 to 17 Sponsor: Other Protocol IDs: CDR0000686545, GPOH-COALL-08-09, EUDRACT-2009-012758-18, EU-21076, NCT01228331
4.	Combination Chemotherapy With or Without Rituximab in Treating Younger Patients With Stage III-IV Non-Hodgkin Lymphoma or B-Cell Acute Leukemia Phase: Phase III, Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and under Sponsor: NCI, Other Protocol IDs: CDR0000732604, COG-ANHL1131, ANHL1131, NCT01595048
5.	Three Different Therapy Regimens in Treating Patients With Previously Untreated Hodgkin Lymphoma Phase: Phase III Type: Treatment Status: Active Age: 18 to 65 Sponsor: Other Protocol IDs: CDR0000633503, GOELAMS-LH2007, GOELAMS-ID-RCB#2007-A01079-44, INCA-RECF0754, AMGEN-GOELAMS-LH2007, NCT00920153
6.	Low-Dose Prednisone or Methylprednisolone in Treating Patients With Newly Diagnosed Acute Graft-versus-Host Disease Phase: Phase III Type: Supportive care Status: Active Age: Not specified Sponsor: NCI, Other Protocol IDs: 2327.00, NCI-2010-00323, P01CA018029, NCT00929695
7.	Trial of FFP+HDMP+Rituximab for Ultra-high Risk Chronic Lymphocytic Leukemia Phase: Phase III Type: Treatment Status: Active Age: 18 to 80 Sponsor: Other Protocol IDs: JSPH-CLL-001, NCT01670812
8.	Phase II Study of Umbilical Cord Blood as a Source of Hematopoietic Stem Cells for Transplantation in Children With Malignant or Non-Malignant Diseases. Note: The information about this trial has not been updated by the sponsor/principal investigator/lead organization. Cancer.gov cannot verify the accuracy of the information. Phase: Phase II Type: Treatment Status: Active Age: 21 and under Sponsor: Other Protocol IDs: PSCI-2003-232, NCT00084695
9.	a Phase II Study in Primary Central Nervous System Lymphoma Phase: Phase II Type: Treatment Status: Active Age: 18 to 75 Sponsor: Other Protocol IDs: T1406, NCT00455286
10.	Donor Stem Cell Transplant in Treating Young Patients With Acute Myeloid Leukemia With Monosomy 7, -5/5q-, High FLT3-ITD AR, or Refractory or Relapsed Acute Myelogenous Leukemia Phase: Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 1 month to 30 years Sponsor: NCI, Other Protocol IDs: CDR0000572744, COG-AAML05P1, AAML05P1, NCT00553202
11.	Phase II Study of Nonmyeloablative Conditioning Regimen Comprising Cyclophosphamide, Fludarabine Phosphate, Anti-thymocyte Globulin, and Total-Body Irradiation Followed By Donor Umbilical Cord Blood Transplantation and Haploidentical Related Donor CD34+ Peripheral Blood Stem Cell Transplantation in Patients With Severe Aplastic Anemia or Myelodysplastic Syndromes Associated With Severe Neutropenia Refractory to Immunosuppressive Therapy Phase: Phase II Type: Treatment Status: Active Age: 8 to 55 Sponsor: NHLBI Protocol IDs: NHLBI-08-H-0046, 08-H-0046, NCT00608413
12.	Combination Chemotherapy, Rituximab, and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Relapsed Stage II, Stage III, or Stage IV Follicular Non-Hodgkin Lymphoma Phase: Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: NCI, Other Protocol IDs: 05-0303-04, P30CA023074, CDR0000597508, HSC#0567, UARIZ-SRC17899, UARIZ-HSC-0567, 05-0303-01, NCT00732498
13.	Donor Stem Cell Transplant After Busulfan, Fludarabine, Methylprednisolone, and Antithymocyte Globulin in Treating Patients With Bone Marrow Failure Syndrome Phase: Phase II Type: Treatment Status: Active Age: 75 and under Sponsor: Other Protocol IDs: CDR0000600351, AMC-UUCM-2008-0038, 2008-0038, NCT00731328
14.	Combination Chemotherapy With or Without Donor Stem Cell Transplant in Treating Patients With Acute Lymphoblastic Leukemia Phase: Phase II Type: Treatment Status: Active Age: 18 to 60 Sponsor: NCI Protocol IDs: NCI-2009-00800, S0805, CDR0000624250, U10CA032102, SWOG-S0805, NCT00792948
15.	Phase II Study of a High-Risk Pediatric Treatment Regimen in Adult Patients With Newly Diagnosed Acute Lymphoblastic Leukemia. Note: The information about this trial has not been updated by the sponsor/principal investigator/lead organization. Cancer.gov cannot verify the accuracy of the information. Phase: Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Approved-not yet active Age: 18 to 50 Sponsor: NCI Protocol IDs: OSU-08066, OSU 08066, 2008C0112, DFCI-06254, NCT01005758
16.	Mismatched Donor Lymphocyte Infusions for Relapsed Disease Following Allogeneic Stem Cell Transplantation Phase: Phase II Type: Treatment Status: Active Age: 8 to 75 Sponsor: NHLBI Protocol IDs: 090087, 09-H-0087, NCT00859586
17.	Donor Stem Cell Transplant or Bone Marrow Transplant in Treating Patients With Acute Myeloid Leukemia in Remission Phase: Phase II Type: Treatment Status: Active Age: 15 to 75 Sponsor: Other Protocol IDs: CDR0000659891, AMC-UUCM-2009-0579, 2009-0579, NCT01020734
18.	Ofatumumab and High-dose Methylprednisolone in Patients With Chronic Lymphocytic Leukemia (CLL) Phase: Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: 100429, NCT01191190
19.	Study of Ofatumumab and ESHAP for the Treatment of Hodgkin's Lymphoma Phase: Phase II Type: Treatment Status: Active Age: 18 to 75 Sponsor: Other Protocol IDs: O-ESHAP-LH-2009, 2009-016026-13, NCT01195766
20.	Reduced-intensity Conditioning Allogeneic Hematopoietic Cell Transplantation Phase: Phase II Type: Treatment Status: Active Age: 16 and over Sponsor: Other Protocol IDs: Allo-039, NCT01252784
21.	R-ESHAP Followed by Autologous Transplantation for Refractory or Relapsed Diffused Large B-cell Lymphoma Phase: Phase II Type: Treatment Status: Active Age: 18 to 65 Sponsor: Other Protocol IDs: LMTG 11-01, NCT01278602
22.	Etoposide, Methylprednisolone, High-dose Cytarabine and Oxaliplatin (ESHAOx) for Refractory or Relapsed Hodgkin's Lymphoma (HL) Phase: Phase II Type: Treatment Status: Active Age: 18 to 75 Sponsor: Other Protocol IDs: NCCCTS-10-524, NCT01300156
23.	Alloreactive Haploidentical Natural Killer (NK) Cells With Busulfan and Fludarabine/ATG Phase: Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 0 to 70 Sponsor: NCI, Other Protocol IDs: 2010-0099, NCT01390402
24.	Acute Promyelocytic Leukemia (APL) Treated With ATRA, Arsenic Trioxide and Gemtuzumab Ozogamicin Phase: Phase II Type: Treatment Status: Active Age: 10 and over Sponsor: Other Protocol IDs: 2010-0981, NCT01409161
25.	Hyper-CVAD and Ponatinib in Ph-Positive and/or BCR-ABL Positive Acute Lymphoblastic Leukemia (ALL) Phase: Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: 2011-0030, NCT01424982